Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide

被引:93
作者
Buechner, SA
Wernli, M
Harr, T
Hahn, S
Itin, P
Erb, P
机构
[1] Univ Basel, Inst Med Microbiol, CH-4003 Basel, Switzerland
[2] Univ Basel, Kantonsspital, Dept Dermatol, CH-4031 Basel, Switzerland
关键词
basal cell carcinoma; apoptosis; CD95; ligand; IFN-alpha;
D O I
10.1172/JCI119814
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Basal cell carcinoma (BCC) is the most common skin cancer in humans, and although metastasis rarely occurs, the tumor cells are nevertheless able to invade and destroy the surrounding tissue, Intralesional injection of IFN-alpha has been found to be highly effective in inducing BCC regression by an unknown mechanism, We show that in untreated patients, BCC cells express CD95 ligand, but not the receptor, which may allow tumor expansion by averting the attack of activated CD95 receptor-positive lymphoid effector cells, The CD95 ligand of BCC cells is functional as CD95-positive cells incubated on BCC cryosections become apoptotic and are lysed, In IFN-alpha-treated patients BCC cells express not only CD95 ligand but also CD95 receptor, whereas the peritumoral infiltrate that mainly consists of CD4+ T cells predominantly contains CD95 receptor and only few CD95 ligand-positive cells, Thus, in treated patients BCC most likely regresses by committing suicide through apoptosis induction via CD95 receptor-CD95 ligand interaction.
引用
收藏
页码:2691 / 2696
页数:6
相关论文
共 46 条
  • [1] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [2] BOTTOMLEY WW, 1991, J DERMATOL TREAT, V2, P15
  • [3] INTERFERON-ALPHA INCREASES THE FREQUENCY OF INTERFERON-GAMMA-PRODUCING HUMAN CD4+ T-CELLS
    BRINKMANN, V
    GEIGER, T
    ALKAN, S
    HEUSSER, CH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) : 1655 - 1663
  • [5] BUECHNER SA, 1995, DERMATOLOGY BASEL, V191, P173
  • [6] BUJA LM, 1993, ARCH PATHOL LAB MED, V117, P1208
  • [7] USE OF RECOMBINANT INTERFERON ALFA-2B IN THE TREATMENT OF BASAL-CELL CARCINOMA
    CHIMENTI, S
    PERIS, K
    DICRISTOFARO, S
    FARGNOLI, MC
    TORLONE, G
    [J]. DERMATOLOGY, 1995, 190 (03) : 214 - 217
  • [8] INTRALESIONAL INTERFERON THERAPY FOR BASAL-CELL CARCINOMA
    CORNELL, RC
    GREENWAY, HT
    TUCKER, SB
    EDWARDS, L
    ASHWORTH, S
    VANCE, JC
    TANNER, DJ
    TAYLOR, EL
    SMILES, KA
    PEETS, EA
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (04) : 694 - 700
  • [9] Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
    Friesen, C
    Herr, I
    Krammer, PH
    Debatin, KM
    [J]. NATURE MEDICINE, 1996, 2 (05) : 574 - 577
  • [10] IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION
    GAVRIELI, Y
    SHERMAN, Y
    BENSASSON, SA
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 493 - 501